Pfizer has announced a revision of its profit forecast for 2025, now expecting an adjusted profit between $3 and $3.15 per share, compared to the previous estimate of $2.90–$3.10, due to solid performance and cost reductions. Quarterly revenues were $16.65 billion, slightly above estimates, but 6% lower than the previous year, influenced by decreased demand for the Comirnaty vaccine and the Paxlovid treatment. Net profit was $3.54 billion, impacted by a one-time tax of $1.35 billion. Pfizer maintains its total revenue estimate for 2025 between $61 and $64 billion and plans to cut costs by $7.7 billion by 2027. The company benefits from an agreement with the Trump administration to reduce drug prices in the U.S. in exchange for tariff exemptions. Pfizer is diversifying its portfolio through acquisitions in oncology and continues to develop drugs, despite declining sales of Covid products. Pfizer's shares have dropped by 7% since the beginning of the year.
Sources
Pfizer majorează prognoza de profit, în pofida scăderii vânzărilor
Pfizer a depăşit estimările privind rezultatele financiare şi a majorează prognoza de profit, în pofida scăderii vânzărilor
Pfizer își majorează prognoza de profit, după rezultate peste așteptări în trimestrul trei
Latest News
14:40
Calea Victoriei records the highest rent increase in Europe, following an annual rise of 29%
14:22
Real Madrid has reached an agreement with Arda Guler to extend his contract
14:17
MoND has begun preparations for the December 1 parade / More than 2,000 military personnel and 130 pieces of military equipment will participate
13:59
Pete Hegseth visits Colombia for talks on military cooperation and shared security
13:49
ANRE: The number of prosumers rose to nearly 395,000 in September
See more news